1. Home
  2. ALZN

as 05-17-2024 4:00pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Health Care

Medicinal Chemicals and Botanical Products

Nasdaq

Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.

Founded: 2016 Country:
United States
United States
Employees: N/A City: ATLANTA
Market Cap: 4.1M IPO Year: 2021
Target Price: N/A AVG Volume (30 days): 82.6K
Analyst Decision: N/A Number of Analysts: N/A
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -1.87 EPS Growth: N/A
52 Week Low/High: $0.44 - $11.91 Next Earning Date: 03-25-2024
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

Share on Social Networks:

Stock Insider Trading Activity of Alzamend Neuro Inc. (ALZN)

Name Ticker Relationship Date Transaction Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
AULT MILTON C III ALZN Director10% Owner Apr 19 '24 Buy $0.69 1,000 $688.20 771,699 SEC Form 4
AULT MILTON C III ALZN Director10% Owner Apr 1 '24 Buy $0.91 334 $304.24 770,699 SEC Form 4
AULT MILTON C III ALZN Director10% Owner Mar 28 '24 Buy $1.06 2,000 $2,127.00 770,365 SEC Form 4
AULT MILTON C III ALZN Director10% Owner Jan 5 '24 Buy $1.02 5,000 $5,092.50 768,365 SEC Form 4
AULT MILTON C III ALZN 10% Owner Dec 22 '23 Buy $0.92 200 $184.84 166,866 SEC Form 4
AULT MILTON C III ALZN 10% Owner Dec 22 '23 Buy $0.90 500 $450.00 26,032 SEC Form 4